PoojaHingoraniMD

Pediatric Hematology & Oncology • Houston, TX

Assistant Professor, Pediatrics, University of Arizona College of Medicine

Join to view full profile

Dr. Hingorani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hingorani's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6620

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineFellowship, Pediatric Hematology/Oncology, 2005 - 2008
SUNY Downstate Health Sciences UniversityResidency, Pediatrics, 2002 - 2005
Maulana Azad Medical CollegeClass of 2000

Certifications & Licensure

AZ State Medical License 2008 - 2025
TX State Medical License 2019 - 2022
OK State Medical License 2020 - 2021
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

1 citations
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.
Douglas Harrison, Jonathan Gill, Michael Roth, Pooja Hingorani, Wendong Zhang
Pediatric Blood & Cancer. 2023-01-01
15 citations
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncolo...
Pooja Hingorani, Mark Krailo, Allen Buxton, Paul Hutson, Paul M Sondel
European Journal of Cancer. 2022-09-01
9 citations
Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang
Molecular Cancer Therapeutics. 2022-08-02